ITGAX and neoplasm: In this study, we found that tumor-bearing WT mice treated with a STAT3 inhibitor showed a reduction in the proportion of CD11b+Gr-1+ MDSCs (including M-MDSCs and G-MDSCs) and an increase in the proportion of CD11b+CD11c+ and CD3+ cells (Fig. S2J–K).